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of intergenerational discounting. CONCLUSIONS: Cost-
effectiveness analysis will increasingly play an informative role in
policy analysis of public health interventions even though it is not
clear what discount rate is appropriate in each case. However,
especially for programmes characterized by long-term dimin-
ished risk of disease, death or sequel avoided, possibility of
disease eradication, and substantial intergenerational impact,
there are no convincing arguments favouring the use of subjective
time preferences when setting ofﬁcial discount rates for applica-
tion in social project evaluation.
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OBJECTIVES: In cost-effectiveness analysis, we aim to account
for all future costs and beneﬁts for all patients who are currently
eligible for a new health technology and who will become eligible
in the future. METHODS: We adapt the fundamental concept
from epidemiology of the incidence and prevalence of a disease to
cost-effectiveness analysis. We deﬁne the prevalent cohort as
those patients eligible to switch from the comparator to the new
technology at the time the new technology is introduced. Next,
we introduce the concept of multiple future incident cohorts. The
incident cohort starting t years in the future consists of those
patients who ﬁrst become eligible for the new technology t years
in the future. Currently cost-effectiveness analyses worldwide
consider only either the prevalent cohort, the incident cohort in
only the ﬁrst year, or a mixture of the two. RESULTS: On
average, patients in the prevalent cohort are older and at a more
advanced stage of illness than patients in the incident cohort. If
the cost and beneﬁt discount rates differ, we show mathemati-
cally that the cost-effectiveness of all technologies will be sub-
stantially affected by our method. Otherwise, the incremental
cost-effectiveness ratio will not change for acute conditions, but
may change substantially for chronic conditions, particularly for
chronic progressive conditions. CONCLUSIONS: We suggest
that analyses capture the costs and beneﬁts arising from the
prevalent cohort and all future incident cohorts. If our method
had been used in the past, some health technologies would have
appeared substantially more cost-effective, others substantially
less cost-effective. If possible, parameter values (e.g. average age,
disease severity) for both the incident and prevalent cohorts
should be obtained from the literature. Otherwise, we describe
how such parameters can be estimated.
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OBJECTIVES: Economic evaluation(EE) incorporate some
degree of uncertainty and variability that arises in a number of
ways. Uncertainty represents lack of perfect knowledge on the
part of the analyst and may be reduced by further measurement
and variability represents heterogeneity or diversity in a popula-
tion that is irreducible by additional measurements (Spanish-
guidelines proposal). This paper tries to shed light on the need to
separate uncertainty and variability in the EE. METHODS: We
propose the Probabilistic Sensitivity Analysis (PSA) as an efﬁcient
methodology to treat uncertainty associated to the model
“inputs”. In PSA, a single variable (or subset of variables) is
allowed to vary within its speciﬁed probability distribution, and
repeat-run sampling-based simulations are performed to produce
a weighted distribution of output estimates. It is proposed a
bayesian estimation of the results of a target parameter
[q|Data] = [Data|q]*[q]/[Data] subsequently to PSA as an
improvement of the method. We propose calculating the Baye-
sian interval of probability (BIP) [q|a,b] of the costs associated
with treatment during the PSA calculations(it has been assumed
that [q|a,b] ª Beta(a,b)[UNKNOWN NODETYPE 9]), deﬁned as
those that have an interval probability “high” to contain the
parameter; equivalent to frequentist conﬁdence interval
P(qmin  q  qmax) = 1 - a[UNKNOWN NODETYPE 9],
using Markov Chains Monte-Carlo but measured as a probabil-
ity not as conﬁdence (a based). RESULTS: We have studied
different scripts using WinBugs and FirstBayes packages for cal-
culating of the estimated costs BIP in a PSA, simulating highly
skewed distributions of costs. The separation of uncertainty and
variability can affect the study results and policy-making deci-
sions in a non-negligible manner and the best methodology to
treat the uncertainty is PSA. CONCLUSIONS: Furthermore this
paper is a brief introduction to the decision models, their relation
to Bayesian decision theory, and the tools typically used to
describe the uncertainties involved presenting an improvement in
the PSA using a BIP of the estimated parameters as a robust
method.
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Decision-making about resource allocation for guideline imple-
mentation to change clinical practice is inevitably undertaken in
a context of uncertainty surrounding the cost-effectiveness of
both clinical guidelines and implementation strategies. Recently,
a model has been developed in which monetary values are
assigned to health outcomes and economic evidence on guide-
lines and strategies is combined with information on clinical
practice to determine the scope of cost-effective guideline imple-
mentation. Adopting a net beneﬁt approach, the model over-
comes problems with the use of combined ratio statistics when
analyzing decision uncertainty concerning clinical practice
change. OBJECTIVES: The stochastic application of the model is
demonstrated for informing decision-making about the adoption
of an audit and feedback strategy for implementing a guideline
recommending intensive blood glucose control in type 2 diabetes
in primary care in The Netherlands. METHODS: An integrated
Bayesian approach to decision modelling and evidence synthesis
is adopted using Markov Chain Monte Carlo simulation in
WinBUGs. Data on model parameters is gathered from various
sources, with the effectiveness of audit and feedback being
estimated using a pooled, random effects meta-analysis model.
Decision uncertainty is illustrated using cost-effectiveness accept-
ability curves (CEACs) and frontier (CEAF). RESULTS: Deci-
sions about whether to adopt the guidance on blood glucose
control and whether to adopt audit and feedback for its imple-
mentation alter over the range of maximum values that decision-
makers are willing to pay for health gain. Through
simultaneously incorporating uncertain economic evidence on
both guidance and implementation strategy, the CEACs and
CEAF show an increase in decision uncertainty concerning guide-
line implementation. CONCLUSIONS: The stochastic applica-
tion in diabetes care demonstrates that the model provides a
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simple and useful tool for quantifying and exploring the (com-
bined) uncertainty associated with decision-making about adopt-
ing guidelines and implementation strategies and, therefore, for
informing decisions about efﬁcient resource allocation to change
clinical practice.
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OBJECTIVES: Estimation of cost-of-illness typically involves
the analysis of skewed medical costs that include large outliers.
Log transformations are frequently used to overcome these
problems. Linear regression models (OLS) are then applied to
the transformed data. The estimated model coefﬁcients are
retransformed back to the linear scale using the smearing
approach. Implementing this approach in statistical packages
requires customized programming. We propose an alternative to
using log transformations: Generalized Linear Models (GLM)
with a log link function. We compare the performance of both
models in estimating cost-of-illness. METHODS: We derived
data from a large administrative database representing 143,593
discharges from 39 US hospitals from January 2004 to Decem-
ber 2005. We estimated total medical costs among hospitalized
patients attributable to hyponatremia. Using a cross-validation
approach, we compared the performance of two models: log
transformed OLS with smearing and GLM with a log link func-
tion and a normal error distribution. We used the Root Mean
Squared Error (RMSE) and the Mean Absolute Error (MAE) to
assess model performance. Covariates in both models included
patient age, gender, race, geographic region, Deyo-Charlson
comorbidity index, primary diagnosis, teaching status of hospi-
tal, and admission source. All analyses were contacted using
SAS®. RESULTS: The GLM with log-link and a normal error
distribution had both the smallest RMSE (23,688) and MAE
(11,304) compared to the log transformed OLS with smearing
(24,057 and 11,392, respectively). Furthermore, by using GLM,
there was no need to compute a retransformation estimate, since
the log link function relates the response mean to the original
scale. CONCLUSIONS: In this cross-validation study, GLM
outperformed OLS with smearing. GLM is easier to implement
using SAS® with no need for retransformation estimates. Because
of its ease of use and statistical accuracy, GLM is a useful alter-
native to log-transformed OLS models with smearing, when
estimating cost-of-illness.
PMC14
A FRAMEWORK FOR REAL-WORLD ECONOMIC EVALUATION
BY INCORPORATING IMPLEMENTATION PARAMETERS
Grutters JP1, Joore MA2
1Maastro Clinic, Maastricht,The Netherlands, 2University Hospital
Maastricht, Maastricht,The Netherlands
OBJECTIVES: Reimbursement decisions are often supported by
economic evaluations based on randomised controlled trials
(RCTs). A problem with RCTs is that they usually deviate from
daily practice. Hence, reimbursement decisions are based on
perfect-world assessments of cost-effectiveness. In daily practice,
the technology is likely to be less cost-effective for instance due to
lower compliance. To make real-world reimbursement decisions,
factors that potentially inﬂuence the cost-effectiveness should be
considered. These factors are implementation factors, and sto-
chastic in nature. This study presents a framework that incorpo-
rates the implementation of a technology directly into the
economic evaluation, thus anticipating on potentially less than
perfect implementation. This results in real-world economic
evaluations. METHODS: The framework allows for a stepwise
consideration of the net beneﬁt (NB) of a technology in different
states of the world: 1) perfect-world (NB under perfect imple-
mentation); 2) real-world (NB under expected implementation);
and 3) improved-world (NB after intervention to improve imple-
mentation). Step 1 tells us whether the technology could be
cost-effective. Step 2 gives us the real world cost-effectiveness.
The difference between the NB of step 1 and 2 gives the upper
bound of the value of improving implementation. Step 3 tells us
whether it is cost-effective to invest in speciﬁc interventions to
improve implementation. The implementation factors are sto-
chastic, therefore in each step parameter uncertainty is addressed
in probabilistic sensitivity analyses, and the value of reducing
uncertainty is examined in value of information analyses.
RESULTS: As a case we used a Markov model that examines the
cost-effectiveness of direct hearing aid provision versus provision
by referral. Two stochastic implementation parameters were
incorporated: patient compliance and professional uptake. The
upper bound of the value of improving implementation was €50
million (patient compliance), €23 (professional uptake) and €72
million in total. This suggests that implementation interventions
may be valuable (results presented at the conference).
METHODS: CONCLUSIONS: This framework allows for real-
word economic evaluations to inform policy decisions.
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In 1996 the Washington Panel controversially recommended
valuing productivity costs (PC) in terms of QALYs. While this
recommendation was criticised, the Panel’s assumption, that
respondents in health state valuation (HSV) exercises take
income losses into account, could not be countered since there
was no evidence regarding what people consider in HSV exer-
cises. If they do consider income losses and if this changes HSV’s,
then all past economic evaluations that have included PC in the
numerator may have double counted these costs. Alternatively, if
respondents do not consider income losses then all past economic
evaluations that have not included PC in the numerator have
failed to account for sizeable societal costs. OBJECTIVES: To
recapture the debate surrounding the appropriate method for
including PC in health economic evaluations, to identify empiri-
cal evidence addressing the assumptions made by the Washington
Panel and to recommend a research agenda for the future.
METHODS: In this review we ﬁrst present and discuss the
human capital and friction cost approaches for capturing PC.
Then, the Washington Panel approach is highlighted and dis-
cussed. Next, we identify, outline and critically appraise the
existing empirical studies that attempt to address the assumption
that respondents to HSV exercises take income effects into
account. Finally, we outline a research agenda for the future that
will help to determine the most appropriate method for including
PC. RESULTS AND CONCLUSIONS: Only six empirical
studies were identiﬁed. The studies differ substantially in
methods and results and drawing general conclusions from them
is difﬁcult. Overall, it seems that not explicitly mentioning the
inclusion of income will induce a minority of respondents to
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